An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer

Launched by CITY OF HOPE MEDICAL CENTER · Apr 1, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on developing a new blood test, called a liquid biopsy, that can help doctors determine the specific type of primary liver cancer a patient has. Sometimes, it can be challenging for doctors to tell if a patient has hepatocellular carcinoma (the most common type of liver cancer) or intrahepatic cholangiocarcinoma (a different type affecting the bile ducts in the liver). The researchers are using advanced technology, including machine learning, to analyze tiny particles called exosomes in the blood to make this distinction clearer before any surgery is performed.

To participate in this study, individuals must have a confirmed diagnosis of either hepatocellular carcinoma or intrahepatic cholangiocarcinoma and must have provided a blood sample before starting any treatment aimed at curing the cancer. The trial is open to all adults aged 65 to 74 and is currently recruiting participants. For those who qualify, taking part in this study may help improve how doctors diagnose and treat liver cancer in the future. Participants will provide a blood sample, and the results could contribute to better understanding and care for liver cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • A histologically confirmed diagnosis of hepatocellular carcinoma
• • A histologically confirmed diagnosis of intrahepatic cholangiocarcinoma
• • Received standard diagnostic and staging procedures as per local guidelines
• • Availability of at least one blood-derived sample, drawn before receiving any curative-intent treatment
• Exclusion Criteria:
• • Lack of or inability to provide informed consent
• • Synchronous hepatocellular carcinoma and intrahepatic cholangiocarcinoma
• • Primary liver cancer other than hepatocellular carcinoma or intrahepatic cholangiocarcinoma
• • Secondary liver cancer